In previous studies, the effect of HET0016, a potent inhibitor of arachidonic acid metabolites 20-HETE production, GW2580, a colony stimulation factor 1 receptor (CSF1R) antagonists, temozolomide (TMZ), Vatalanib, a VEGFR2 receptor tyrosine kinase inhibitor, SB225002, a CXCR2 inhibitor on the growth of GBM have been reported but systematic investigations were not performed regarding TME composition and survival [7, 8, 10, 20, 63]. The gene discussed is CXCR2; the disease is glioblastoma.